First Manhattan’s Arbutus Biopharma ABUS Stock Holding History

First Manhattan’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$63K	Hold	14,000	–	–	﹤0.01%	744
2025 Q4	$67.3K	Hold	14,000	–	–	﹤0.01%	722
2025 Q3	$63.6K	Hold	14,000	–	–	﹤0.01%	708
2025 Q2	$43.3K	Hold	14,000	–	–	﹤0.01%	693
2025 Q1	$48.9K	Hold	14,000	–	–	﹤0.01%	669
2024 Q4	$45.8K	Hold	14,000	–	–	﹤0.01%	674
2024 Q3	$53.9K	Hold	14,000	–	–	﹤0.01%	675
2024 Q2	$43.3K	Hold	14,000	–	–	﹤0.01%	658
2024 Q1	$36.1K	Hold	14,000	–	–	﹤0.01%	948
2023 Q4	$35K	Hold	14,000	–	–	﹤0.01%	940
2023 Q3	$28.4K	Hold	14,000	–	–	﹤0.01%	970
2023 Q2	$32.2K	Hold	14,000	–	–	﹤0.01%	961
2023 Q1	$42.4K	Buy	+14,000	New	+$39.5K	﹤0.01%	940
2014 Q4	–	Sell	-100	Closed	-$2K	–	1466
2014 Q3	$2K	Buy	+100	New	+$1.63K	﹤0.01%	1367

Other funds holding ABUS

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

WCM

Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

First Manhattan's ABUS Position: Q1 2026 in Review

First Manhattan held its Arbutus Biopharma (ABUS) position steady in Q1 2026 at 14,000 shares worth $63K. The position accounts for ﹤0.01% of the portfolio, ranked #744.

First Manhattan first reported a position in ABUS in Q3 2014 and has held it in 14 quarters since. The position peaked at $67.3K in Q4 2025. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

First Manhattan held 14,000 shares of Arbutus Biopharma worth $63K as of Q1 2026.
First Manhattan left its Arbutus Biopharma share count unchanged in Q1 2026.
Arbutus Biopharma made up ﹤0.01% of First Manhattan's portfolio in Q1 2026, its #744 holding.
First Manhattan first reported a position in Arbutus Biopharma in Q3 2014 and has held it in 14 quarters since.
First Manhattan's Arbutus Biopharma position peaked at $67.3K in Q4 2025.
167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on First Manhattan's 13F filing for Q1 2026, filed 15 May 2026.